# Multiplexed Droplet Digital Nucleic Acid Amplification Technologies for HIV Diagnosis

> **NIH NIH N43** · VIVID BIOINNOVATIONS, PBC · 2023 · $299,903

## Abstract

Development of Diagnostics to Differentiate HIV Infection from Vaccine-Induced Seropositivity: The overarching goal of this program is to support the development of new serological and nucleic acid assays that can identify HIV infection while avoiding false-positive results due to vaccine-induced seropositivity (VISP), with high sensitivity and specificity. These next generation assays should be developed to address one or all applications/indications of HIV tests, namely: (1) laboratory based tests; ((2) point-of-care and clinical practices; and (3) self-testing. This contract aims to develop a droplet digital nucleic acid test to diagnose HIV infection.

## Key facts

- **NIH application ID:** 10927089
- **Project number:** 75N93023C00008-0-9999-1
- **Recipient organization:** VIVID BIOINNOVATIONS, PBC
- **Principal Investigator:** ROBIN PRINCE
- **Activity code:** N43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $299,903
- **Award type:** —
- **Project period:** 2023-08-01 → 2024-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10927089

## Citation

> US National Institutes of Health, RePORTER application 10927089, Multiplexed Droplet Digital Nucleic Acid Amplification Technologies for HIV Diagnosis (75N93023C00008-0-9999-1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10927089. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*